Literature DB >> 3568953

Chyloperitoneum with collateral lymphatic drainage involving abdominal skin.

L E Perino, J M Vierling.   

Abstract

A 58-year-old man with poorly differentiated lymphoma and chyloperitoneum, who developed periumbilical white vesicular skin lesions, is presented. These skin lesions represent collateral lymphatic drainage pathways for the chyloperitonium as evidenced by drainage of chylous fluid from these lesions and communication with the peritoneum as demonstrated by intraperitoneal 99mTc sulfur colloid injection.

Entities:  

Mesh:

Year:  1987        PMID: 3568953     DOI: 10.1007/bf01296168

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  8 in total

1.  LYMPHATIC DYNAMICS IN CERTAIN ABNORMAL STATES.

Authors:  S WALLACE; L JACKSON; G D DODD; R R GREENING
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1964-06

2.  Absorption of serum from the peritoneal cavity.

Authors:  H E RAYBUCK; L ALLEN; W S HARMS
Journal:  Am J Physiol       Date:  1960-12

3.  The effects of obliteration of the diaphragmatic lymphatic plexus on serous fluid.

Authors:  L ALLEN; H E RAYBUCK
Journal:  Anat Rec       Date:  1960-05

4.  The lymphatic circulation in lymphedema.

Authors:  J B KINMONTH; G W TAYLOR
Journal:  Ann Surg       Date:  1954-02       Impact factor: 12.969

5.  The lymphatic drainage of plasma from the peritoneal cavity of the cat.

Authors:  F C COURTICE; A W STEINBECK
Journal:  Aust J Exp Biol Med Sci       Date:  1950-03

6.  A study of ascites using lymphoscintigraphy with 99m Tc-sulfur colloid.

Authors:  G Coates; R S Bush; N Aspin
Journal:  Radiology       Date:  1973-06       Impact factor: 11.105

7.  Collateral lymphatic circulation after thoracic duct ligature in dogs.

Authors:  V de Freitas; N L Zorzetto; J C Prates; G Seullner
Journal:  Anat Anz       Date:  1979

8.  Evaluation and management of chylous ascites.

Authors:  O W Press; N O Press; S D Kaufman
Journal:  Ann Intern Med       Date:  1982-03       Impact factor: 25.391

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.